Bahaa Ibrahim Saeed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bahaa Ibrahim Saeed has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Abhayveer Singh
Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, India
1 shared publication Ali G. Alkhathami
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia
1 shared publication- Amera Bekhatroh Rashed
Nursing Department, College of Applied Medical Sciences, Jouf University, Saudi Arabia
1 shared publication Ashok Kumar Bishoyi
Department of Microbiology, Faculty of Science, Marwadi University Research Center, Marwadi University, Rajkot, Gujarat, 360003, India
1 shared publication- Daniel Alex Anand
Department of Biomedical, Sathyabama Institute of Science and Technology, Chennai, India
1 shared publication - Deepak Bhanot
Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, India
1 shared publication
Latest Publications
- 26 December 2025
- Published by Springer Nature in Medical Oncology
- Vol. 43 (2) , 76
Exosomal non-coding RNAs as emerging drivers of immune dysregulation in melanoma
Melanoma is a type of skin cancer that starts in melanocytes. It is estimated to increase by 2050 based on prediction studies. Exosomes have been identified as crucial intracellular mediators by carrying the donor-derived cargoes from stromal cells, immune cells, and even tumor cells, thereby affecting the function of recipient cells in a context-dependent manner. Although EVs can transport biologically active compounds like proteins, lipids, RNA, and DNA, their exact role remains unclear. The past few years have seen a surge in studies on tumor-associated cargo in exosomes, particularly concerning ncRNAs. The function of exosomal non-coding RNAs in melanoma’s immunopathogenesis has been reviewed in detail in the current narrative review article. Exosomal ncRNAs have the potential to develop novel diagnostic and therapeutic targets in melanoma.
- 26 December 2025
- Published by Springer Nature in Medical Oncology
- Vol. 43 (2) , 76
Exosomal non-coding RNAs as emerging drivers of immune dysregulation in melanoma
Melanoma is a type of skin cancer that starts in melanocytes. It is estimated to increase by 2050 based on prediction studies. Exosomes have been identified as crucial intracellular mediators by carrying the donor-derived cargoes from stromal cells, immune cells, and even tumor cells, thereby affecting the function of recipient cells in a context-dependent manner. Although EVs can transport biologically active compounds like proteins, lipids, RNA, and DNA, their exact role remains unclear. The past few years have seen a surge in studies on tumor-associated cargo in exosomes, particularly concerning ncRNAs. The function of exosomal non-coding RNAs in melanoma’s immunopathogenesis has been reviewed in detail in the current narrative review article. Exosomal ncRNAs have the potential to develop novel diagnostic and therapeutic targets in melanoma.
- 9 August 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (9) , 422
From cell cycle control to cancer therapy: exploring the role of CDK1 and CDK2 in tumorigenesis
The cyclin-dependent kinase (CDK) family comprises one of the most common types of serine/threonine kinases responsible for controlling many cellular processes through the action of the dynamics of these enzymes. The CDKs are regulators of cellular processes, ranging from cell cycle progression, an integral step of cellular lifespan involved in its division and growth, to the expression of genes and the transfer of genetic information from DNA to RNA. CDK-related pathology is primarily based on the dysregulation of CDK, resulting in improper coordination of the cell cycle and leading to uncontrolled proliferation. The CDK1 involved in the G2 to M-phase transition interacts with CENPF, PVT1, and TFCP2L1, which affects chromosome segregation and cell proliferation. Besides the previously described partners, namely PRDX2 and C/EBPα, the CDK2 responsible for the G1/S transition has also been shown to bind TBK1 and modulate DNA synthesis and cell cycle checkpoints. Such mechanisms of action contribute to oncogenesis through interactions, including roles for lncRNAs and miRNAs in modulating the expression and activity of CDKs. Their importance in cancer has made CDK1/2 critical candidates for anticancer drug targeting. The dysregulation of CDK1/2 manifests in cancer pathology, which is, in turn, associated with an uncoordinated normal cell cycle and resultant proliferation. This study aims to provide a comprehensive overview of the diverse functions of CDK1 and CDK2 in cancer, thereby facilitating the exploration of their therapeutic potential and the development of novel cancer therapy designs. The complexity of targeting CDK1 and CDK2 highlights the importance of their regulation during cancer development. It indicates their substantial promise as valid targets for therapy, in vitro and vivo studies, and human sample analysis.
- 9 August 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (9) , 422
From cell cycle control to cancer therapy: exploring the role of CDK1 and CDK2 in tumorigenesis
The cyclin-dependent kinase (CDK) family comprises one of the most common types of serine/threonine kinases responsible for controlling many cellular processes through the action of the dynamics of these enzymes. The CDKs are regulators of cellular processes, ranging from cell cycle progression, an integral step of cellular lifespan involved in its division and growth, to the expression of genes and the transfer of genetic information from DNA to RNA. CDK-related pathology is primarily based on the dysregulation of CDK, resulting in improper coordination of the cell cycle and leading to uncontrolled proliferation. The CDK1 involved in the G2 to M-phase transition interacts with CENPF, PVT1, and TFCP2L1, which affects chromosome segregation and cell proliferation. Besides the previously described partners, namely PRDX2 and C/EBPα, the CDK2 responsible for the G1/S transition has also been shown to bind TBK1 and modulate DNA synthesis and cell cycle checkpoints. Such mechanisms of action contribute to oncogenesis through interactions, including roles for lncRNAs and miRNAs in modulating the expression and activity of CDKs. Their importance in cancer has made CDK1/2 critical candidates for anticancer drug targeting. The dysregulation of CDK1/2 manifests in cancer pathology, which is, in turn, associated with an uncoordinated normal cell cycle and resultant proliferation. This study aims to provide a comprehensive overview of the diverse functions of CDK1 and CDK2 in cancer, thereby facilitating the exploration of their therapeutic potential and the development of novel cancer therapy designs. The complexity of targeting CDK1 and CDK2 highlights the importance of their regulation during cancer development. It indicates their substantial promise as valid targets for therapy, in vitro and vivo studies, and human sample analysis.